Neuron protection as a therapeutic target in acute ischemic stroke

Current Topics in Medicinal Chemistry

Volumn 9, Issue 14, 2009, Pages 1317-1334

  Tuttolomondo, Antonino ^a   Di Sciacca, Riccardo ^a   Di Raimondo, Domenico ^a   Arnao, Valentina ^a   Renda, Chiara ^a   Pinto, Antonio ^a   Licata, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3K3A ACTIVATED PROTEIN C; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR ANTAGONIST; BACLOFEN; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; BLOOD CLOTTING FACTOR; BW 619C87; CALCIUM CHANNEL BLOCKING AGENT; CITICOLINE; DISUFENTON SODIUM; DIZOCILPINE; DROTRECOGIN; KAINIC ACID RECEPTOR ANTAGONIST; KYNURENIC ACID; KYNURENINE; LANICEMINE; LY 393615; MEMANTINE; MUSCIMOL; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NICARDIPINE; NIMODIPINE; NORPHENAZONE; REACTIVE OXYGEN METABOLITE; SB 201823A; SB 221420A; SIPATRIGINE; SODIUM CHANNEL BLOCKING AGENT; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGITATION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DIZZINESS; DRUG HALF LIFE; DRUG INHIBITION; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; NAUSEA; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; REVIEW; SIDE EFFECT; STROKE PATIENT; STUPOR; VOMITING;

BRAIN ISCHEMIA; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; STROKE;

EID: 74249111108     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789869646     Document Type: Review

References (78)

1. National Institute of Neurological Disorders, Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24), 1581-7.
2. Green, A.R. Protecting the brain, the search for a clinically effective neuroprotective drug for stroke. Crit Rev Neurobiol. 2004; 16(1-2), 91-7.
3. Hallenbeck, J.M.; Dutka, A.J. Background review and current concepts of reperfusion injury. Arch Neurol. 1990; 47(11), 1245-54.
4. Lo, E.H.; Dalkara, T.; Moskowitz, M.A. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4, 399-415.
5. Fisher, M.; Brott, T.G. Emerging therapies for acute ischemic stroke, new therapies on trial. Stroke. 2003; 34, 359-61.
6. Onteniente, B.; Rasika, S.; Benchoua, A.; Guegan, C. Molecular pathways in cerebral ischemia, cues to novel therapeutic strategies. Mol Neurobiol 2003; 27, 33-72.
7. Koroshetz, W.J.; Moskowitz, M.A. Emerging treatments for stroke in humans. Trends Pharmacol Sci 1996; 17, 227-33.
8. Liu, H.; Friedman, L.K.; and Kaur, J. Perinatal seizures preferentially protect CA1 neurons from seizure-induced damage in prepubescent rats. Seizure. 2006; 15, 1-16.
9. Hirayasu, Y. and Wada, J.A. Convulsive seizures in rats induced by Nmethyl- D-aspartate injection into the massa intermedia. Brain Res. 1992; 577, 36-40
10. Mathis, C. and Ungerer, A. Comparative analysis of seizures induced by intracerebroventricular administration of NMDA, kainate and quisqualate in mice. Exp. Brain Res. 1992; 88, 277-282.
11. Ludvig, N.; Mishra, P.K.; Yan, Q.S.; Lasley, S.M.; Burger, R.L.; and Jobe, P.C. The paradoxical effect of NMDA receptor stimulation on electrical activity of the sensorimotor cortex in freely behaving rats, Analysis by combined EEG-intracerebral microdialysis. Synapse. 1992; 12, 87-98
12. Cotton, D.B.; Hallak, M.; Janusz, C.; Irtenkauf, S.M.; Berman, R.F. Central anticonvulsant effects of magnesium sulfate on N-methyl-D- aspartate- induced seizures. Am. J. Obstet. Gynecol. 1993; 168, 974-978.
13. Hallak, M.; Irtenkauf, S.M.; Janusz, C.A.; and Cotton, D.B. Stimulation and inhibition of N-methyl-D-aspartate receptors in rats, Developing a seizure model. Am. J. Obstet. Gynecol. 1993 3, 695-700.
14. Schenk, S. and Partridge, B. Effects of acute and repeated administration of N-methyl-D-aspartate (NMDA) into the ventral tegmental, Locomotor activating effects of NMDA and cocaine. Brain Res. 1997; 769, 225-232.
15. Ludvig, N. and Tang, H.M. Cellular electrophysiological changes in the hippocampus of freely behaving rats during local microdialysis with epileptogenic concentration of N-methyl-D-aspartate. Brain Res. Bulletin 2000; 51, 233-240
16. Mitani, A.; Namba, S.; Ikemune, K.; Yanase, H.; Arai, T.; and Kataoka,K. Postischemic enhancements of N-methyl-D-aspartic acid (NMDA) and non-NMDA receptor-mediated responses in hippocampal CA1 pyramidal neurons. J. Cereb. Blood Flow Metab. 1998; 10, 1088-1098.
17. Nakanishi, N.; Tu, S.; Shin, Y.; Cui, J.; Kurokawa, T.; Zhang, D.; Chen, H.S.; Tong, G.; Lipton, S.A. Neuroprotection by the NR3A subunit of the NMDA receptor. J Neurosci. 2009; Apr 22; 29(16), 5260-5.
18. Skaper, S.D.; Facci, L.; Strijbos, P.J. Neuronal protein kinase signaling cascades and excitotoxic cell death. Ann N Y Acad Sci. 2001; Jun; 939, 11-22.
19. Dambinova, S.A.; Khounteev, G.A.; Izykenova, G.A.; Zavolokov, I.G.; Ilyukhina, A.Y.; Skoromets, A.A. Blood test detecting autoantibodies to N-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin Chem. 2003; Oct; 49(10), 1752-62.
20. Gigler, G.; Szénási, G.; Simó, A.; Lévay, G.; Hársing, L.G. Jr, Sas, K.; Vécsei, L.; Toldi, J. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol. 2007; Jun 14; 564(1-3), 116-22.
21. Ahmad, A.S.; Yun, Y.T.; Ahmad, M.; Maruyama, T.; Doré, S. Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation. Neurotox Res. 2008; Dec; 14(4), 343-51.
22. Terashima, A.; Pelkey, K.A.; Rah, J.C.; Suh, Y.H.; Roche, K.W.; Collingridge, G.L.; McBain, C.J.; Isaac, J.T. An essential role for PICK1 in NMDA receptor-dependent bidirectional synaptic plasticity. Neuron. 2008; Mar 27; 57(6), 872-82.
23. Vandresen-Filho, S.; de Araújo, Herculano, B.; Franco, J.L.; Boeck, C.R.; Dafre, A.L.; Tasca, C.I. Evaluation of glutathione metabolism in NMDA preconditioning against quinolinic acid-induced seizures in mice cerebral cortex and hippocampus. Brain Res. 2007; Dec 12; 1184, 38-45.
24. Xu, J.; Zhang, Q.G.; Li, C.; Zhang, G.Y. Subtoxic N-methyl-D-aspartate delayed neuronal death in ischemic brain injury through TrkB receptor- and calmodulin-mediated PI-3K/Akt pathway activation. Hippocampus. 2007; 17(7), 525-37.
25. Lees, K.R.; Dyker, A.G.; Sharma, A.; Ford, G.A.; Ardron, M.E.; Grosset, D.G. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients, a dose-ranging study. Stroke 2001; 32, 466-472.
26. Diener, H.C.; AlKhedr, A.; Busse, O.; Hacke, W.; Zingmark, P.H.; Jonsson, N. et al. . Treatment of acute ischaemic stroke with the lowaffinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study. J Neurol 2002; 249, 561-568.
27. Muir, K.W.; Lees, K.R. (1995). Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995; 26, 503-513.
28. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients, a dose-ranging study. Lees, K.R.; Dyker, A.G.; Sharma, A.; Ford, G.A.; Ardron, M.E.; Grosset, D.G. Stroke. 2001; Feb; 32(2), 466-72.
29. Diener, H.C.; AlKhedr, A.; Busse, O.; Hacke, W.; Zingmark, P.H.; Jonsson, N.; Basun, H. Study group. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist ARR15896AR. A safety and tolerability study. J Neurol. 2002; May; 249(5), 561-8
30. Marshall, J.W.; Cummings, R.M.; Bowes, L.J.; Ridley, R.M.; Green, A.R. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke. 2003; Sep; 34(9), 2228-33.
31. Diener, H.C.; Lees, K.R.; Lyden. P.; Grotta, J.; Davalos, A.; Davis, S.M.; Shuaib, A.; Ashwood, T.; Wasiewski, W.; Alderfer, V.; Hårdemark, H.G.; Rodichok, L. SAINT I and II Investigators. NXY-059 for the treatment of acute stroke, pooled analysis of the SAINT I and II Trials. Stroke. 2008; Jun; 39(6), 1751-8.
32. Aarts, M.M.; Tymianski, M. Molecular mechanisms underlying specificity of excitotoxic signaling in neurons. Curr Mol Med. 2004; Mar; 4(2), 137-47.
33. Kiessling, M.; Gass, P. Stimulus-transcription coupling in focal cerebral ischemia. Brain Pathol. 1994; Jan; 4(1), 77-83.
34. Friedman, L.K.; Belayev, L.; Alfonso, O.F.; Ginsberg, M.D. Distribution of glutamate and preproenkephalin messenger RNAs following transient focal cerebral ischemia. Neuroscience. 2000; 95(3), 841-57.
35. Lin, C.H.; Chen, P.S.; Gean, P.W. Glutamate preconditioning prevents neuronal death induced by combined oxygen-glucose deprivation in cultured cortical neurons. Eur J Pharmacol. 2008; Jul 28; 589(1-3), 85-93.
36. Bakiri, Y.; Hamilton, N.B.; Káradóttir, R.; Attwell, D. Testing NMDA receptor block as a therapeutic strategy for reducing ischaemic damage to CNS white matter. Glia. 2008; Jan 15; 56(2), 233-40.
37. May, P.C.; Robison, P.M.; Fuson, K.S. Stereoselective neuroprotection by novel 2,3-benzodiazepine non-competitive AMPA antagonist against non-NMDA receptor-mediated excitotoxicity in primary rat hippocampal cultures. Neurosci Lett. 1999; Mar 12; 262(3), 219-21.
38. Gressens, P.; Spedding, M.; Gigler, G.; Kertesz, S.; Villa, P.; Medja, F.; Williamson, T.; Kapus, G.; Levay, G.; Szenasi, G.; Barkoczy, J.; Harsing, L.G. Jr. The effects of AMPA receptor antagonists in models of stroke and neurodegeneration. Eur J Pharmacol. 2005; Sep 5; 519(1-2), 58-67.
39. Weiser, T.; Brenner, M.; Palluk, R.; Bechtel, W.D.; Ceci, A.; Brambilla, A.; Ensinger, H.A.; Sagrada, A.; Wienrich, M. BIIR 561 CL, a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties. J Pharmacol Exp Ther. 1999; Jun; 289(3), 1343-9.
40. Takahashi, M.; Kohara, A.; Shishikura, J.; Kawasaki-Yatsugi, S.; Ni, J.W.; Yatsugi, S.; Sakamoto, S.; Okada, M.; Shimizu-Sasamata, M.; Yamaguchi, T. YM872, a selective, potent and highly water-soluble alpha-amino-3- hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist. CNS Drug Rev. 2002; Winter; 8(4), 337-52.
41. Suzuki, M.; Sasamata, M.; Miyata, K. Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model. Brain Res. 2003; Jan 3; 959(1), 169-72.
42. Dahlbäck, B.; Villoutreix, B.O. Regulation of blood coagulation by the protein C anticoagulant pathwaypathway, novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol. 2005; 25, 1311-1320.
43. Joyce, D.E.; Gelbert, L.; Ciaccia, A.; Dehoff, B.; Grinnell, B.W. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001; 276, 11199-11203.
44. Cheng, T.; Liu, D.; Griffin, J.H.; et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003; 9, 338-342.
45. Domotor, E.; Benzakour, O.; Griffin, J.H.; et al. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood. 2003; 101, 4797- 4801.
46. Mosnier, L.O.; Griffin, J.H. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor. Biochem J. 2003; 373, 65-70. 19.
47. Riewald, M.; Petrovan, R.J.; Donner, A.; Mueller, B.M.; Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002; 296, 1880-1882.
48. Shibata, M.; Kumar, S.R.; Amar, A.; Fernandez, J.A.; Hofman, F.; Griffin, J.H.; Zlokovic, B.V. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation. 2001; Apr 3; 103(13), 1799-805.
49. Guo, H.; Singh, I.; Wang, Y.; Deane, R.; Barrett, T.; Fernández, J.A.; Chow, N.; Griffin, J.H.; Zlokovic, B.V. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci. 2009; Mar; 29(6), 1119-3.
50. Wang, Y.; Thiyagarajan, M.; Chow, N.; Singh, I.; Guo, H.; Davis, T.P.; Zlokovic, B.V. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke. 2009; May; 40(5), 1864-9.
51. Slemmer, J.E.; Shacka, J.J.; Sweeney, M.I.; Weber, J.T. Antioxidants and free radical scavengers for the treatment of stroke, traumatic brain injury and aging. Curr Med Chem. 2008; 15(4), 404-14.
52. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007; 39(1), 44-84.
53. Shinohara, Y.; Saito, I.; Kobayashi, S.; Uchiyama, S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis. 2009; 27(5), 485-92.
54. Ueno, Y.; Zhang, N.; Miyamoto, N.; Tanaka, R.; Hattori, N.; Urabe, T. Edaravone attenuates white matter lesions through endothelial protection in a rat chronic hypoperfusion model. Neuroscience. 2009 Aug 18; 162(2), 317-327.
55. Ohta, Y.; Takamatsu, K.; Fukushima, T.; Ikegami, S.; Takeda, I.; Ota, T.; Goto, K.; Abe, K. Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction. Intern Med. 2009; 48(8), 593-6.
56. Clark, W.M.; Williams, B.J.; Selzer, K.A.; Zweifler, R.M.; Sabounjian, L.A.; Gammans, R.E. A randomized efficacy trial of citicoline in patients with acute ischemic stroke. Stroke. 1999; Dec; 30(12), 2592-7.
57. Clark, W.M.; Wechsler, L.R.; Sabounjian, L.A.; Schwiderski, U.E. Citicoline Stroke Study Group. A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 2001; Nov 13; 57(9), 1595-602.
58. Barone, F.C.; Lysko, P.G.; Price, W.J.; Feuerstein, G.; al-Baracanji, K.A.; Benham, C.D.; Harrison, D.C.; Harries, M.H.; Bailey, S.J.; Hunter, A.J. SB 201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischemia in rats and mice. Stroke. 1995; Sep; 26(9), 1683-9.
59. Kawaguchi, K.; Henshall, D.C.; Simon, R.P. Parallel dose-response studies of the voltage-dependent Na+ channel antagonist BW619C89, and the voltage-dependent Ca2+ channel antagonist nimodipine, in rat transient focal cerebral ischaemia. Eur J Pharmacol. 1999; Jan 8; 364(2-3), 99-105.
60. Campbell, C.A.; Barone, F.C.; Benham, C.D.; Hadingham, S.J.; Harries, M.H.; Harling, J.D.; Hills, J.M.; Lewis, V.A.; Mackay, K.B.; Orlek, B.S.; White, R.F.; Parsons, A.A.; Hunter, A.J. Characterisation of SB-221420-A - a neuronal Ca(2+) and Na(+) channel antagonist in experimental models of stroke. Eur J Pharmacol. 2000; Aug 11; 401(3), 419-28.
61. O'Neill, M.J.; Hicks, C.A.; Ward, M.A.; Osborne, D.J.; Wishart, G.; Mathews, K.S.; McLaughlin, D.P.; Stamford, J.A.; McCarty, D.R.; Patrick, K.E.; Roman, C.; Fleisch, J.H.; Gilmore, J.; Boot, J.R. LY393615, a novel neuronal Ca(2+) and Na(+) channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemia. Brain Res. 2001; Jan 5; 888(1), 138-149.
62. Bailey, S.J.; Wood, N.I.; Samson, N.A.; Rothaul, A.L.; Roberts, J.C.; King, P.D.; Hamilton, T.C.; Harrison, D.C.; Hunter, A.J. Failure of isradipine to reduce infarct size in mouse, gerbil, and rat models of cerebral ischemia. Stroke. 1995; Nov; 26(11), 2177-83.
63. Shah, Q.A.; Georgiadis, A.; Suri, M.F.; Rodriguez, G.; Qureshi, A.I. Preliminary experience with intra-arterial nicardipine in patients with acute ischemic stroke Neurocrit Care. 2007; 7(1), 53-7.
64. Wei, L.; Ying, D.J.; Cui, L.; Langsdorf, J.; Yu, S.P. Necrosis, apoptosis and hybrid death in the cortex and thalamus after barrel cortex ischemia in rats. Brain Res. 2004; Oct 1; 1022(1-2), 54-61.
65. Onténiente, B.; Couriaud, C.; Braudeau, J.; Benchoua, A.; Guégan, C. The mechanisms of cell death in focal cerebral ischemia highlight neuroprotective perspectives by anti-caspase therapy. Biochem Pharmacol. 2003; Oct 15; 66(8), 1643-9.
66. Zhang, H.; Gao, X.; Yan, Z.; Ren, C.; Shimohata, T.; Steinberg, G.K.; Zhao, H. Inhibiting caspase-3 activity blocks beta-catenin degradation after focal ischemia in rat. Neuroreport. 2008; May 28; 19(8), 821-4.
67. Wen, Y.; Onyewuchi, O.; Yang, S.; Liu, R.; Simpkins, J.W. Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res. 2004; May 29; 1009(1-2), 1-8.
68. Xiong, M.; Zhang, T.; Zhang, L.M.; Lu, S.D.; Huang, Y.L.; Sun, F.Y. Caspase inhibition attenuates accumulation of beta-amyloid by reducing beta-secretase production and activity in rat brains after stroke. Neurobiol Dis. 2008; Dec; 32(3), 433-41.
69. Endres, M.; Namura, S.; Shimizu-Sasamata, M.; Waeber, C.; Zhang, L.; Gómez-Isla, T.; Hyman, B.T.; Moskowitz, M.A. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab. 1998; Mar; 18(3), 238-47.
70. Braun, J.S.; Prass, K.; Dirnagl, U.; Meisel, A.; Meisel, C. Protection from brain damage and bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPH. Exp Neurol. 2007; (2), 183-91.
71. Saito, A.; Narasimhan, P.; Hayashi, T.; Okuno, S.; Ferrand-Drake, M.; Chan, P.H. Neuroprotective role of a proline-rich Akt substrate in apoptotic neuronal cell death after stroke, relationships with nerve growth factor. J Neurosci. 2004; Feb 18; 24(7), 1584-93.
72. Wiessner, C.; Sauer, D.; Alaimo, D.; Allegrini, P.R. Protective effect of a caspase inhibitor in models for cerebral ischemia in vitro and in vivo. Cell Mol Biol (Noisy-le-grand). 2000; Feb; 46(1), 53-62.
73. Zhou, C.; Li, C.; Yu, H.M.; Zhang, F.; Han, D.; Zhang, G.Y. Neuroprotection of gamma-aminobutyric acid receptor agonists via enhancing neuronal nitric oxide synthase (Ser847) phosphorylation through increased neuronal nitric oxide synthase and PSD95 interaction and inhibited protein phosphatase activity in cerebral ischemia. J Neurosci Res. 2008; Oct; 86(13), 2973-83.
74. Schwartz-Bloom, R.D. Sah Rgamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. J Neurochem. 2001; Apr; 77(2), 353-71.
75. Zhang, F.; Li, C.; Wang, R.; Han, D.; Zhang, Q.G.; Zhou, C.; Yu, H.M.; Zhang, G.Y. Activation of GABA receptors attenuates neuronal apoptosis through inhibiting the tyrosine phosphorylation of NR2A by Src after cerebral ischemia and reperfusion. Neuroscience. 2007; Dec 19; 150(4), 938-49.
76. Xu, J.; Li, C.; Yin, X.H.; Zhang, G.Y. Additive neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade. Neuropharmacology. 2008; Jun; 54(7), 1029-40.
77. Egashira, N.; Hayakawa, K.; Osajima, M.; Mishima, K.; Iwasaki, K.; Oishi, R.; Fujiwara, M. Involvement of GABA(A) receptors in the neuroprotective effect of theanine on focal cerebral ischemia in mice. J Pharmacol Sci. 2007; Oct; 105(2), 211-4.
78. Baskys, A.; Fang, L.; Bayazitov, I. Activation of neuroprotective pathways by metabotropic group I glutamate receptors, a potential target for drug discovery? Ann N Y Acad Sci. 2005; Aug; 1053, 55-73.